1. Pharma budgets are strengthening
- Accelerating spend and broad planned increases lower near-term demand risk for pharma advertising.
DOC
DOCS
USD 33.18
-46.98% · 1Y
Latest: mixed
Price
Full synthesis
Viewpoint Synthesis
Bull Thesis
Pharma demand is improving, while stronger adoption could support monetization and reduce near-term growth risk.
2. Product engagement may widen
- Improving Ask adoption offers a foothold for deeper engagement, though revenue impact remains unproven.
3. Peer re-rating supports valuation
- A higher peer-based objective signals room for valuation support if operating trends hold.
Bear Thesis
Valuation assumes durable compounding, but market-level growth and uncertain AI monetization leave downside risk elevated.
1. Growth may not justify the multiple
- A compounding-growth multiple on market-level growth raises estimate risk and caps upside.
- Paying nearly VEEV's multiple despite slower growth weakens relative risk/reward.
- An Underperform stance despite a higher target underscores how far shares exceed assessed value.
2. AI may redistribute rather than expand spend
- Mixed AI budgets signal unresolved ROI, delaying incremental platform monetization.
- Prior launches broadened usage without lifting total spend, making AI-driven wallet expansion uncertain.
Opinion timeline
Opinion Timeline
Bull Plane
TIME
Bear Plane
Bank of America's 18th pharma survey showed Doximity spend growth accelerating to 2%, the fastest in survey history, with 81% of top-20 pharma respondents planning to increase spend next year.
2026-10-20
Back to thesis
Ask adoption also improved modestly.
2026-10-20
Back to thesis
Bank of America raised its price objective to $23 from $20 on peer re-rating.
PT $23 from $20
2026-10-20
Back to thesis
2026-10-20
AI platform budgets remain mixed as customers assess ROI.
2026-10-20
Back to thesis
Bank of America maintains an Underperform rating, as shares are still well above its target.
2026-10-20
Back to thesis
Wells Fargo downgrades DOCS to Underweight, arguing the stock now carries a compounding-growth multiple despite only market-level growth and limited evidence that AI will expand wallet share. Wells Fargo says AI is more likely to shift spend across Doximity...
2026-08-10
Back to thesis
2026-08-10
Wells Fargo downgraded the stock to Underweight, arguing it carries a compounding-growth multiple despite only market-level growth and limited evidence that AI will expand wallet share.
2026-08-10
Back to thesis
AI is more likely to shift spend across Doximity’s existing platform than create meaningful incremental pharma budgets, as prior module launches broadened usage without materially increasing total spend.
2026-08-10
Back to thesis
Wells Fargo sees unfavorable risk/reward at roughly 16x 2027E versus VEEV at 17x despite VEEV’s faster growth, and set an $18 price target.
2026-08-10
Back to thesis
Sources and method
Research through 2026-10-20 · 2026-08-10 to 2026-10-20 · 2 source reports.
| Range | Prices through |
|---|---|
| 1W | |
| 1M | |
| 3M | |
| 6M | |
| 1Y | |
| 2Y | |
| 3Y |